Treatment of adrenocortical carcinoma: a case report and review of the literature.
A case report of adrenocortical carcinoma is presented, and its natural history and treatment are discussed. Adrenocortical carcinoma is a rare malignant disease. The mean survival time for untreated patients is less than three months. The tumor is classified as functioning or nonfunctioning depending on biochemical and clinical evidence of steroid overproduction. Surgical resection of the tumor is the primary treatment. Chemotherapy is indicated for antitumor and antihormonal effects. Mitotane is a direct adrenolytic, and is the only drug currently available that has extended survival in patients with this disease. Its clinical usefulness is limited by its gastrointestinal and neurological toxicity. Aminoglutethimide inhibits steroid synthesis by blocking the conversion of cholesterol to pregnenolone. It has no antitumor effect in adrenocortical carcinoma, but is effective in relieving the signs and symptoms of excessive hormone production in functioning tumors. Both mitotane and aminoglutethimide have complex mechanisms of action. Their combined use in the treatment of adrenocortical carcinoma requires a complete understanding of their individual actions and awareness of the potential for additive effects, both therapeutic and toxic.
D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy* / Q000601:surgery; D000328:Adult; D000616:Aminoglutethimide / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007700:Kinetics; D008939:Mitotane / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism; D013256:Steroids / Q000627:therapeutic use
D013256:Steroids; D000616:Aminoglutethimide; D008939:Mitotane